Laboratory Tests Required Before Administering Tenecteplase

Essential Laboratory Tests

• The American Heart Association recommends a comprehensive coagulation panel including activated partial thromboplastin time (aPTT), prothrombin time/international normalized ratio (PT/INR), complete blood count with platelet count, and creatinine to assess bleeding risk and ensure safe administration of tenecteplase in patients with acute ischemic stroke 1
• Coagulation parameters including aPTT and PT/INR should be obtained to identify underlying coagulopathies in patients prior to tenecteplase administration 1
• Serum creatinine should be assessed to evaluate kidney function, as renal impairment may affect drug clearance in patients receiving tenecteplase 1
• Blood glucose level should be checked to rule out hypoglycemia as a stroke mimic in patients presenting with acute stroke symptoms 2, 3
• Troponin should be measured to rule out concurrent myocardial infarction in patients with acute ischemic stroke 3

Additional Important Tests

• Electrolytes should be assessed to evaluate for metabolic abnormalities that may mimic stroke symptoms in patients with acute ischemic stroke 1, 3
• Liver function tests should be performed when indicated to assess hepatic function in patients receiving tenecteplase 1

Timing Considerations

• The American College of Cardiology recommends that all laboratory tests should be obtained urgently but should not delay tenecteplase administration in eligible stroke patients 2, 4
• If the patient was receiving heparin therapy before screening, an aPTT must be performed with a result less than 1.5 times the upper limit of normal before tenecteplase administration 1

Clinical Pitfalls to Avoid

• The European Stroke Organisation advises against delaying thrombolysis waiting for non-essential laboratory results in patients with acute ischemic stroke when time-to-treatment is critical 2, 4
• Patients with abnormal coagulation parameters have an increased risk of hemorrhagic complications, according to the European Society of Cardiology 5

Contraindications Based on Laboratory Results

• The American College of Chest Physicians recommends that tenecteplase is contraindicated in patients with active internal bleeding or recent significant bleeding, known bleeding disorders, INR >1.7 in patients on oral anticoagulants, platelet count <100,000/mm³, or severe uncontrolled hypertension (systolic blood pressure >180 mmHg) 1, 5, 6